undamentalytics Newsletter
Sign in

Airsculpt Technologies, Inc. (AIRS) stock

Add to watchlist

Add holding +

NASDAQ: AIRS Nasdaq Health Care Services Next results ~November 9, 2026

D Fundamentals grade

Airsculpt Technologies, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Airsculpt Technologies, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: cash-flow value per share is not positive (net debt exceeds value). We'll show the comparison once resolved.

Airsculpt Technologies, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling13 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds61 adding, 37 cuttingOf 20 active managers that changed their stake, 12 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Airsculpt Technologies files

Where Airsculpt Technologies stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $151m, down 8.7% on a year earlier, a smaller fall than the 11.8% decline a quarter earlier. That puts it 31 of 34 for growth among the health care services companies we cover. Free-cash-flow margin held at 0.5%. Operating margin narrowed to -8.4% from -5.1%. The diluted share count is up 13.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 1 of our 7 financial-health checks.

Our model value for Airsculpt Technologies is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Airsculpt Technologies, Inc.'s trailing-twelve-month revenue fell 8.7% year on year, with a free-cash-flow margin of 0.5%. Where it lags: revenue growth of -8.7% ranks 36 of 41 health care services companies we cover.

Current signal Net income rising while operating cash flow falls: TTM net income grew 17.8% while operating cash flow fell 87.7% — earnings and cash are telling different stories.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Airsculpt Technologies, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 8.7% over the last 12 months.
  • Loss-making. Operating margin is -8.4%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 3.3 points on a year ago.
  • Share dilution. Diluted shares rose 13.3% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 130% and a beta of 3.0 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results: FY2026 Q2

Filed August 10, 2026
Earnings per share
$0.01 against an average estimate of $0.02: missed by 50.0%
Revenue
$43m, down 2.5% on a year earlier
Share reaction
-35.8% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Guidance given
full year 2026 revenue $151m to $157m (full year 2026); adjusted EBITDA $12m to $14m (full year 2026)
Next report
November 9, 2026; average EPS estimate -$0.03

Airsculpt Technologies' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.5%
  • 1 week+42.7%
  • 1 month-5.6%
  • This year-15.7%
  • 1 year-84.0%
  • 5 years-88.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$151M
Operating margin
-8.4%
Net margin
-7.8%
EPS (TTM, diluted)
$-0.18

Growth

Revenue growth
−8.7%
Change in growth rate
+3.1 pts
Share count change
+13.3%

Cash

Free cash flow (TTM)
$760,000
FCF margin
0.5%
Stock pay % of revenue
0.8%

Earnings

Last results
August 10, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results
  3. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Airsculpt Technologies, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: cash-flow value per share is not positive (net debt exceeds value).

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Airsculpt Technologies, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.3%: the 10-year Treasury yield (4.9%) plus a beta of 1.41 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.1 ~$0.7–$5.0 Left out: out of range vs price (0.03x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Airsculpt Technologies, Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$16.48$3.70$7.49$5.19$1.98$1.67
Market value$917m$206m$425m$299m$120m$110m
+ Net debt (− = net cash)$59m$75m$63m$63m$49m$25m
Enterprise value$976m$281m$488m$362m$168m$136m
Multiples
Price / sales 6.9x1.2x2.2x1.7x0.8x0.7x
Price / earnings 86.9x—————
Price / free cash flow 47.0x17.9x30.3x—173.0x145.0x
EV / EBITDA 43.6x80.0x24.4x35.1x137.8x—

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, before the open. Analysts expect revenue of $35m and EPS of −$0.03 (range −$0.03 to −$0.03) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.06 0% $151m −1%
Next −$0.01 +83% $155m +3%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +100.0% on 90 days ago. In the last 30 days, 0 analysts raised Airsculpt Technologies, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Airsculpt Technologies, Inc., last 90 days
−$0.06 −$0.04 −$0.02 $0.00 $0.02 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.03 Current fiscal year, 60 days ago: −$0.03 Current fiscal year, 30 days ago: −$0.03 Current fiscal year, 7 days ago: −$0.02 Current fiscal year, Now: −$0.06 −$0.06 Next fiscal year, 90 days ago: −$0.02 Next fiscal year, 60 days ago: −$0.02 Next fiscal year, 30 days ago: −$0.02 Next fiscal year, 7 days ago: $0.01 Next fiscal year, Now: −$0.01 −$0.01

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.03−$0.02
60 days ago −$0.03−$0.02
30 days ago −$0.03−$0.02
7 days ago −$0.02$0.01
Now −$0.06−$0.01

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.02 $0.01 −50.0%
Mar 2026 −$0.02 −$0.01 +50.0%
Dec 2025 −$0.02 −$0.02 0.0%
Sept 2025 −$0.01 −$0.04 −166.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 10, 2026
  • full year 2026 revenue full year 2026 $151m to $157m Maintained
    “The Company is reaffirming its full year 2026 revenue at the lower end of its guidance range of approximately $151 to $157 million and reducing its adjusted EBITDA outlook to the range of approximately $12 to $14 million.” source
  • adjusted EBITDA full year 2026 $12m to $14m Non-GAAP Lowered
    “The Company is reaffirming its full year 2026 revenue at the lower end of its guidance range of approximately $151 to $157 million and reducing its adjusted EBITDA outlook to the range of approximately $12 to $14 million.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

3 analysts, Oct 2026
Buy133%
Hold267%
Sell00%

Monthly trend

  1. Oct 2026123
  2. Sep 2026123

Counts of recommendations published by analysts covering Airsculpt Technologies, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.2%
of tradable shares
Days to cover
3.28
at average volume
Short interest, 1 month
−4%
to October 15, 2026
Held by institutions
63%
of shares
Held by insiders
42.2%
of shares
Employees
330
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −84.0%

$10.41 on October 31, 2025 to $1.67

ThenNowEffect
Revenue (last 12 months) $165m $151m −8.7%
P/S multiple 3.7x 0.7x −80.1%
Share count 58m 66m −11.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −74.5%

$6.54 on November 3, 2023 to $1.67

ThenNowEffect
Revenue (last 12 months) $181m $151m −16.8%
P/S multiple 2.0x 0.7x −63.8%
Share count 56m 66m −15.2%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
AIRS−78%+102%−31%−62%−16%
Industry peers (median)−25%+6%−6%−6%+15%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
AIRS42%50%33%42%36%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
AIRS−84%−48%−59%−83%−80%
S&P 500−25%−10%−8%−19%−9%

Worst fall since October 29, 2021: 93% from December 30, 2021 to October 26, 2026. Getting back needed a 1374% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.17 – $10.49
From 52-week high
−84.1%
vs 50-day average
−15.5%
vs 200-day average
−46.4%
Volatility (1 year)
130%
Beta vs S&P 500
2.98

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±20.1%
After a week
5 up, 7 down
typical move ±21.4%
After a month
5 up, 7 down
typical move ±37.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 −35.8% −0.3% −38.4% −47.9%
May 8, 2026 +25.7% +1.1% +38.7% +52.6%
April 2, 2026 +13.6% +0.6% −3.3% +26.0%
March 16, 2026 +45.4% +1.3% +50.3% +50.8%
November 7, 2025 −39.6% +1.7% −47.9% −71.7%
August 1, 2025 −8.8% −0.1% −5.6% −5.0%
May 2, 2025 +7.5% +0.9% +32.3% +104.9%
March 14, 2025 −10.5% +2.9% −10.0% −39.6%
January 13, 2025 −17.7% +0.3% −11.5% −4.8%
November 8, 2024 +15.9% +0.5% −9.5% −9.3%
October 24, 2024 +7.3% +0.2% +7.0% +31.6%
August 9, 2024 −12.9% +0.5% +1.8% −5.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Airsculpt Technologies, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Airsculpt Technologies, Inc.
$140M $160M $180M $200M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $189M Revenue (TTM), FY23 Q4: $195.9M Revenue (TTM), FY24 Q1: $197.7M Revenue (TTM), FY24 Q2: $193M Revenue (TTM), FY24 Q3: $188.8M Revenue (TTM), FY24 Q4: $180.4M Revenue (TTM), FY25 Q1: $172.1M Revenue (TTM), FY25 Q2: $165.1M Revenue (TTM), FY25 Q3: $157.6M Revenue (TTM), FY25 Q4: $151.8M Revenue (TTM), FY26 Q1: $151.8M Revenue (TTM), FY26 Q2: $150.7M $150.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $189M
FY23 Q4 $195.9M
FY24 Q1 $197.7M
FY24 Q2 $193M
FY24 Q3 $188.8M
FY24 Q4 $180.4M
FY25 Q1 $172.1M
FY25 Q2 $165.1M
FY25 Q3 $157.6M
FY25 Q4 $151.8M
FY26 Q1 $151.8M
FY26 Q2 $150.7M
Revenue growth, TTM YoY Airsculpt Technologies, Inc.
-20% -10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 14.1% Revenue growth, TTM YoY, FY23 Q4: 16.1% Revenue growth, TTM YoY, FY24 Q1: 12.9% Revenue growth, TTM YoY, FY24 Q2: 6.6% Revenue growth, TTM YoY, FY24 Q3: -0.1% Revenue growth, TTM YoY, FY24 Q4: -7.9% Revenue growth, TTM YoY, FY25 Q1: -13.0% Revenue growth, TTM YoY, FY25 Q2: -14.5% Revenue growth, TTM YoY, FY25 Q3: -16.5% Revenue growth, TTM YoY, FY25 Q4: -15.8% Revenue growth, TTM YoY, FY26 Q1: -11.8% Revenue growth, TTM YoY, FY26 Q2: -8.7% -8.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 14.1%
FY23 Q4 16.1%
FY24 Q1 12.9%
FY24 Q2 6.6%
FY24 Q3 -0.1%
FY24 Q4 -7.9%
FY25 Q1 -13.0%
FY25 Q2 -14.5%
FY25 Q3 -16.5%
FY25 Q4 -15.8%
FY26 Q1 -11.8%
FY26 Q2 -8.7%
Operating margin (TTM) Airsculpt Technologies, Inc.
-10% -5% 0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 1.1% Operating margin (TTM), FY23 Q4: 5.0% Operating margin (TTM), FY24 Q1: 9.6% Operating margin (TTM), FY24 Q2: 4.5% Operating margin (TTM), FY24 Q3: 2.1% Operating margin (TTM), FY24 Q4: -0.9% Operating margin (TTM), FY25 Q1: -8.2% Operating margin (TTM), FY25 Q2: -5.1% Operating margin (TTM), FY25 Q3: -9.2% Operating margin (TTM), FY25 Q4: -7.6% Operating margin (TTM), FY26 Q1: -7.8% Operating margin (TTM), FY26 Q2: -8.4% -8.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 1.1%
FY23 Q4 5.0%
FY24 Q1 9.6%
FY24 Q2 4.5%
FY24 Q3 2.1%
FY24 Q4 -0.9%
FY25 Q1 -8.2%
FY25 Q2 -5.1%
FY25 Q3 -9.2%
FY25 Q4 -7.6%
FY26 Q1 -7.8%
FY26 Q2 -8.4%
FCF margin (TTM) Airsculpt Technologies, Inc.
-5% 0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 8.2% FCF margin (TTM), FY23 Q4: 7.2% FCF margin (TTM), FY24 Q1: 6.8% FCF margin (TTM), FY24 Q2: 1.4% FCF margin (TTM), FY24 Q3: 0.6% FCF margin (TTM), FY24 Q4: -1.5% FCF margin (TTM), FY25 Q1: -3.2% FCF margin (TTM), FY25 Q2: -0.1% FCF margin (TTM), FY25 Q3: 1.6% FCF margin (TTM), FY25 Q4: 0.5% FCF margin (TTM), FY26 Q1: 4.6% FCF margin (TTM), FY26 Q2: 0.5% 0.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 8.2%
FY23 Q4 7.2%
FY24 Q1 6.8%
FY24 Q2 1.4%
FY24 Q3 0.6%
FY24 Q4 -1.5%
FY25 Q1 -3.2%
FY25 Q2 -0.1%
FY25 Q3 1.6%
FY25 Q4 0.5%
FY26 Q1 4.6%
FY26 Q2 0.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 41 63 133 169 196 180 152 151
EBITDA 6 16 22 4 20 10 1 −0
Operating income 1 10 16 −5 10 −2 −12 −13
Net income −2 8 11 −15 −4 −8 −12 −12
Diluted EPS — — −$0.01 −$0.26 −$0.08 −$0.14 −$0.19 −$0.18
Growth (year on year)
Revenue — +52.2% +112.4% +26.6% +16.1% −7.9% −15.8% −8.7%
EBITDA — +178.7% +42.7% −84.3% +468.1% −48.4% −88.2% −107.8%
Operating income — — +57.2% −128.8% — −116.3% — —
Net income — — +39.3% −239.1% — — — —
Margins
EBITDA margin 13.6% 25.0% 16.8% 2.1% 10.2% 5.7% 0.8% −0.2%
Operating margin 1.6% 16.0% 11.8% −2.7% 5.0% −0.9% −7.6% −8.4%
Net margin −5.4% 12.1% 7.9% −8.7% −2.2% −4.4% −7.7% −7.8%
Free-cash-flow margin 1.2% 16.4% 14.6% 6.8% 7.2% −1.5% 0.5% 0.5%
Cash flow
Cash from operations 5 14 27 24 24 11 3 1
Capital spending 4 4 7 13 10 14 2 1
Free cash flow 0 10 20 12 14 −3 1 1
Stock-based pay 0 0 7 29 18 4 2 1
Free cash flow after stock pay 0 10 12 −18 −4 −6 −2 −0
Balance sheet
Cash 5 10 25 10 10 8 8 19
Total debt 0 33 84 85 73 71 57 44
Net debt (negative = net cash) −5 22 59 75 63 63 49 25
Diluted shares — — 56m 56m 57m 58m 60m 66m
Returned to shareholders
Dividends — 0 0 23 0 0 0 —
Total returned — 0 0 23 0 0 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 7 checks passed · June 30, 2026
What it owns · $193m
Short-term assets $27mLonger-term assets $166m
What it owes, and who funded it · $193m
Short-term liabilities $35mLonger-term liabilities $54mShareholders' equity $105m
  • Short-term assets cover short-term liabilities $27m of assets due within a year against $35m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $27m short-term assets against $54m of longer-dated liabilities.
  • More cash than debt $19m of cash against $44m of debt.
  • Debt below 40% of shareholders' equity Debt is 42% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 98% to 42% over five years.
  • A year's operating cash flow covers at least 20% of debt $1m of operating cash flow against $44m of debt.
  • Operating profit covers interest at least five times over Operating income of −$13m against $5m of interest.

From Airsculpt Technologies, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Dividends (TTM)
$0
Returned to shareholders
0%
of free cash flow
Diluted share count
+13.3%
year over year
Total shareholder yield
0.0%
dividends 0.0% + buybacks 0.0% of market value
Sales & admin spending
55.6%
of revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated AIRS NRC PETS RDGT SBC DLHC Median
Revenue, last 12 months $151m $140m $169m $132m $175m $254m $1.2bn
Revenue growth, last 12 months −8.7% −0.2% −20.3% 10.2% −6.9% −29.5% 7.3%
Revenue growth, 3-year average −5.9% −1.9% −13.0% — — −9.5% 11.3%
Revenue growth, latest quarter −2.5% 4.0% −19.9% — 13.4% −46.9% 8.5%
Gross margin — — 27.9% 3.6% 71.9% 24.3% 27.9%
Operating margin −8.4% 10.5% −18.2% −1.4% 37.3% −0.1% 2.3%
Operating margin, 3-year average −3.0% 19.1% −12.6% — 37.3% 3.5% 2.3%
Net margin −7.8% 4.0% −17.3% −0.9% 28.0% −8.5% 1.2%
Cash from operations / revenue 0.8% 21.1% −14.1% −1.1% 35.9% 5.5% 6.1%
Free-cash-flow margin 0.5% 15.5% −16.4% −1.1% 35.3% 5.5% 5.1%
Free-cash-flow margin, 3-year average 0.6% 12.5% −7.3% — — 6.6% 3.6%
Stock pay / revenue 0.8% 8.4% 0.6% 8.6% — 0.5% 1.1%
Change in share count 13.3% −5.2% 2.9% 96.6% 1.4% 2.2% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth -8.7% 7.3% 36 of 41
Change in growth rate Growth +3.1pp +1.1pp 13 of 41
Operating margin Profitability -8.4% 2.6% 30 of 40
Net margin Profitability -7.8% 1.2% 32 of 41
Free-cash-flow margin Cash generation 0.5% 5.1% 28 of 40
Stock pay as % of revenue Cash generation 0.8% 0.9% 12 of 35
Long-term debt as % of assets Balance sheet 17.1% 27.7% 11 of 31
Change in share count Balance sheet 13.3% 0.4% 34 of 39

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$205M
Institutions reporting
103
Shares held vs prior quarter
▲ 10.9%
Positions opened / closed
25 / 10

Top buyers and sellers, Q2 2026: 61 institutions bought and 37 sold ; the biggest buyer was Thrivent Financial For Lutherans (+4.4M shares) and the biggest seller Balyasny Asset Management L.P (−2.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vesey Street Capital Partners, L.L.C. $136M 30.3M 66.5% 0.0%
Thrivent Financial For Lutherans $19.9M 4.4M 9.7% New
Blackrock, Inc. $5.8M 1.3M 2.8% ▲ 59.0%
Wexford Capital LP $3.8M 842K 1.8% ▲ 25.5%
UBS Group AG $3.6M 792K 1.7% ▲ 27.3%
Fourworld Capital Management LLC $3.4M 750K 1.6% ▼ 24.1%
Flputnam Investment Management Co $3.1M 692K 1.5% New
AQR Capital Management LLC $2.1M 471K 1.0% ▲ 52.2%
Geode Capital Management, LLC $2M 451K 1.0% ▲ 22.5%
Gsa Capital Partners LLP $1.9M 425K 0.9% ▲ 65.2%
Centerbook Partners LP $1.8M 392K 0.9% New
Millennium Management LLC $1.7M 373K 0.8% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Airsculpt Technologies, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $2M 13 trades by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $2M net buying
Insider Date Trade Shares Price Value
Chernett Jorey 10% owner April 17, 2026 Buy 40,000 $2.54 $101,600
Chernett Jorey 10% owner April 14, 2026 Buy 20,000 $2.60 $52,000
Chernett Jorey 10% owner April 7, 2026 Buy 60,000 $2.93 $175,800
Chernett Jorey 10% owner April 3, 2026 Buy 90,000 $2.82 $253,800
Chernett Jorey 10% owner March 23, 2026 Buy 50,000 $2.91 $145,500
Chernett Jorey 10% owner March 20, 2026 Buy 40,000 $2.77 $110,800
Chernett Jorey 10% owner March 19, 2026 Buy 77,702 $2.64 $205,133
Chernett Jorey 10% owner March 17, 2026 Buy 83,000 $2.56 $212,480
Chernett Jorey 10% owner March 16, 2026 Buy 105,848 $2.43 $257,211
Chernett Jorey 10% owner March 11, 2026 Buy 88,000 $2.15 $189,200
Chernett Jorey 10% owner March 6, 2026 Buy 45,600 $2.00 $91,200
Chernett Jorey 10% owner March 4, 2026 Buy 30,000 $1.87 $56,100

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 26, 2026 estimated from the company's past filing pattern, not announced

  • August 10, 2026
  • May 8, 2026
  • April 2, 2026
  • March 16, 2026
  • November 7, 2025
  • August 1, 2025

Recent SEC filings

Data status

When each part of this page on Airsculpt Technologies, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Airsculpt Technologies, Inc. in brief

What does Airsculpt Technologies, Inc. do?
Airsculpt Technologies, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
What is Airsculpt Technologies, Inc.'s stock ticker?
Airsculpt Technologies, Inc. trades under the ticker AIRS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Airsculpt Technologies, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Airsculpt Technologies, Inc. reported revenue of $151M, 8.7% lower than a year earlier, according to its SEC filings.
What is Airsculpt Technologies, Inc.'s free cash flow?
Airsculpt Technologies, Inc.'s free-cash-flow margin is 0.5% of revenue over the trailing twelve months, ranking 28 of the 40 health care services companies we cover.
Who are Airsculpt Technologies, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vesey Street Capital Partners, L.L.C., Thrivent Financial For Lutherans and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Airsculpt Technologies, Inc.'s market cap?
On November 2, 2026, Airsculpt Technologies, Inc.'s market capitalisation was about $110M and net debt of $25.4M. Market figures come from third-party market data and may be delayed.
Does Airsculpt Technologies, Inc. pay a dividend?
Airsculpt Technologies, Inc. reported no dividend payments in its trailing twelve months of filings.
How much debt does Airsculpt Technologies, Inc. have?
Airsculpt Technologies, Inc.'s debt-to-equity ratio is 41.6%, from its latest balance sheet (97.9% five years earlier). The financial health section below sets out its other solvency checks.
Who are Airsculpt Technologies, Inc.'s competitors?
In our Health Care Services peer group, the companies closest to Airsculpt Technologies, Inc. are NRC Health, Petmed Express Inc, Ridgetech Inc., SBC Medical Group Holdings Inc and DLH Holdings Corp. The side-by-side comparison below sets their revenue, margins and growth against Airsculpt Technologies, Inc.'s.
Are insiders buying or selling Airsculpt Technologies, Inc. stock?
Over the last 12 months, Airsculpt Technologies, Inc.'s directors and officers reported 13 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Airsculpt Technologies, Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Airsculpt Technologies, Inc. announces its own schedule.